Oral white patches in a national sample of medical HIV patients in the era of HAART

Community Dentistry and Oral Epidemiology

Volumn 33, Issue 2, 2005, Pages 99-106

  Marcus, Marvin ^a   Maida, Carl A ^a   Freed, James R ^a   Younai, Fariba ^a   Coulter, Ian D ^a   Der Martirosian, Claudia ^a   Liu, Honghu ^b   Freed, Benjamin ^a   Guzmán Becerra, Norma ^c   Shapiro, Martin ^b  

^a UCLA SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

HAART; HIV AIDS; Oral candidiasis; Oral symptoms; Protease inhibitors

Indexed keywords

ADOLESCENT; ADULT; AGE; ANALYSIS OF VARIANCE; ARTICLE; ETHNIC GROUP; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; LEUKOPLAKIA; MALE; MIDDLE AGED; MOUTH MUCOSA; PATHOLOGY; RISK; SELF DISCLOSURE; SEX DIFFERENCE; THRUSH; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANDIDIASIS, ORAL; ETHNIC GROUPS; FEMALE; HIV INFECTIONS; HUMANS; INTERVIEWS; LEUKOPLAKIA, HAIRY; MALE; MIDDLE AGED; MOUTH MUCOSA; ODDS RATIO; SELF DISCLOSURE; SEX FACTORS; UNITED STATES;

EID: 20144387284     PISSN: 03015661     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0528.2004.00171.x     Document Type: Article

References (31)

1. Harris P. The degaying of AIDS. A & U AIDS 1999;8:46-9.
2. Centers for Disease Control and Prevention. Update: trends in AIDS incidence, deaths and prevalence - United States, 1996. MMWR 1997;46:165-73.
3. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV Disease in an urban community. New Eng J Med 1994;11:763-8.
4. Smith S. A longitudinal study of access and drug utilization in a cohort with HIV disease. Pharmacy. Ann Arbor, MI: University of Michigan Press; 1996.
5. Easterbrook PJ, Keruly JC, Creagh-Kirk T, Richman DD, Chaisson RE, Moore RD. Racial and ethnic differences in outcome in zudovudine-treated patients with advanced HIV disease. JAMA 1991;266:2713-8.
6. Mor V, Fleishman JA, Dresser M, Piette J. Variation in health service use among HIV-infected patients. Med Care 1992;30:17-29.
7. Graham NM, Jacobson LP, Kuo V, Chmiel JS, Morgenstern H, Zucconi SL. Access to therapy in the multicenter AIDS cohort study, 1989-1992. J Clin Epidemiol 1994;47:1003-12.
8. Weinert M, Grimes RM, Lynch DP. Oral manifestations of HIV infection. Ann Int Med 1996;125:485-96.
9. Greenspan D, Greenspan JS. HIV-related oral disease. Lancet 1996;348:729-33.
10. Silverman S Jr, Gallo JW, McKnight ML, Mayer P, deSanz S, Tan MM. Clinical characteristics and management responses in 85 HIV-infected patients with oral candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:402-7.
11. Campo J, Romero JD, Castilla J, Garcia S, Rodriguez C, Bascones A. Oral Candidiasis as a clinical marker related to viral load, and CD4 lymphocyte percentage in HIV-infected patients. J Pathol Med 2001;31:5-10.
12. Greenspan D, Komaroff E, Redford M, Phelan JA, Navazesh M, Alves Mario AF et al. Oral mucosal lesions and viral load in women's interagency HIV study (WHIS) J Acq Immunodef Syn 2000;25:44-50.
13. Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JJ. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 2001;357:1411-2.
14. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(Suppl. 1):S5-14.
15. Karon JM, Fleming PL, Steketee RW, De Cock KM. HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health 2001;91:1060-8.
16. Eyeson JD, Warnakulasuriya K, Johnson NW. Prevalence and incidence of oral lesions- the changing scene. Oral Dis 2000;6:267-73.
17. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr. Changing prevalence of oral manifestations of human immunodeficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89:299-304.
18. King MD, Reznik DA, O'Daniels CM, Larsen NM, Osterholt D, Blumberg HM. Human papilloma virus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002;34:641-8.
19. Ceballos-Salobrena A, Gaitán-Cepeda LA, Ceballos-Garcia L, Lezma-Del Valle D. Oral lesions in HIV/ AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care and STDs 2000;14:627-35.
20. Tavitian A, Raufman JP, Rosenthal LE. Oral candidiasis as a marker for esophageal candidiasis in the acquired immunodeficiency syndrome. Ann Int Med 1986;104:54-5.
21. Katz MH, Greenspan D, Westenhouse J. Progression to AIDS in HIV-infected homosexual and bisexual men with hairy leukoplakia and oral candidiasis. AIDS 1992;6:95-100.
22. Shapiro MF, Berk ML, Berry SH, Emmons CA, Athey LA, Hsia DC et al. National probability samples in studies of low-prevalence diseases. Part I: Perspectives and lessons learned from the HIV Cost and Services Utilization Study. Health Serv Res 1999;34(5 Pt 1):951-68.
23. Frankel MR, Shapiro MF, Duan N, Morton SC, Berry SH, Brown JA et al. National probability samples in studies of low-prevalence diseases. Part II: Designing and implementing the HIV cost and services utilization study sample. Health Serv Res 1999;34(5 Pt 1):969-92.
24. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
25. Diggle PJ, Liang KY, Zeger SL. The analysis of longitudinal data. Oxford: Oxford University Press; 1994.
26. Dobalian A, Andersen RM, Stein JA, Hays RD, Cunningham WH, Marcus M. The impact of HIV on oral health and subsequent use of dental services. J Publ Health Dent 2003;63:78-85.
27. Coulter ID, Marcus M, Freed JR, Der-Martitosian C, Cunningham WE, Andersen RM et al. J Dent Res 2000;79:1356-61.
28. Cunningham WE, Markson LE, Andersen RM, Crystal SH, Fleishman JA, Golin C et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. J Acquir Immune Defic Syndr 2000; 2:115-23.
29. Gifford AL, Cunningham WE, Heslin KC, Andersen RM, Nakazono T, Lieu DK et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med 2002;346:1373-82.
30. Patton LL. Ability of HIV/AIDS patients to self-diagnose oral opportunistic infections. Community Dent Oral Epidemiol 2001;29:23-9.
31. Younai FS, Marcus M, Freed JR, Coulter ID, Cunningham W, Der-Martirosian C et al. Self-reported oral dryness and HIV disease in a national sample of patients receiving medical care. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:629-36.